Propanc Biopharma Net Loss Widens to $7.9M in H1 FY2026 as Expenses Surge
Propanc Biopharma reported a net loss of $7.9 million for the six months ending December 31, 2025, more than 10 times the $784,493 loss posted in the same period a year earlier. Operating expenses jumped to $8.3 million from $504,172 as the Delaware-based biotech burned through cash.
Propanc Biopharma reported a net loss of $7.9 million for the six months ending December 31, 2025, more than 10 times the $784,493 loss posted in the same period a year earlier. Operating expenses jumped to $8.3 million from $504,172 year over year. Read more earnings reports.
The biotech company posted a quarterly net loss of $3.1 million for the three months ending December 31, 2025, compared to a $430,183 loss in the prior-year quarter. Operating expenses for the quarter reached $3.7 million, up sharply from $213,382 a year earlier.
Cash used in operations totaled $2.9 million for the six-month period, compared to $216,786 in the prior-year period. The company raised $3.5 million from financing activities during the half, compared to $270,515 in the same period last year.
Total assets declined to $15.1 million as of December 31, 2025, from $19.6 million at the end of June 2025. Current assets dropped to $7.7 million from $8.4 million over the same period.
Total liabilities fell to $3.7 million from $5.7 million, driven by a reduction in current liabilities to $3.6 million from $5.6 million. Accounts payable decreased to $957,483 from $1.2 million. Long-term debt declined sharply to $55,000 from $537,921.
Stockholders equity decreased to $10.5 million as of December 31, 2025, from $13.9 million six months earlier. The company's accumulated deficit widened to $134.5 million from $125.6 million.
Research and development expenses totaled $80,162 for the six-month period, down from $116,102 in the prior-year period. For the December quarter alone, R&D spending was $19,961, compared to $54,388 a year earlier.
The company reported basic and diluted loss per share of $0.69 for the six months ending December 31, 2025, compared to a loss of $67.65 per share in the prior-year period. Weighted average shares outstanding increased to 12.8 million from 11,597 shares, reflecting what appears to be a significant change in share structure.
Common shares outstanding stood at 13.4 million as of December 31, 2025, up from 11.6 million six months earlier. Additional paid-in capital rose to $143.6 million from $138.2 million.
| Financial Metric | H1 FY2026 | H1 FY2025 |
|---|---|---|
| Net Loss | $7,929,132 | $784,493 |
| Operating Expenses | $8,328,298 | $504,172 |
| R&D Expenses | $80,162 | $116,102 |
| Cash from Operations | ($2,938,207) | ($216,786) |
| Total Assets | $15,111,532 | $19,631,808 |
| Total Liabilities | $3,659,267 | $5,725,616 |
| Stockholders Equity | $10,452,265 | $13,906,192 |
| Loss Per Share (Basic) | ($0.69) | ($67.65) |